Verastem
Logotype for Verastem Inc

Verastem (VSTM) investor relations material

Verastem Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Verastem Inc
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026

Commercial performance and market uptake

  • Achieved over 50% sales growth from Q2 to Q4, beating analyst consensus for three consecutive quarters.

  • Drug adoption is broad, with strong uptake in both major academic centers and large community practices.

  • Average patient duration on therapy is 18 months, supporting a recurring revenue model.

  • Reimbursement is robust for both on-label and off-label use, including KRAS wild type cases.

  • A new promotional campaign is launching to position the therapy as the preferred post-frontline option.

Clinical development and trial updates

  • Confirmatory trial (RAMP 301) completed accrual, with a final readout expected around mid-next year.

  • Trial size increased from 270 to 300 patients to maintain statistical power, with positive interim feedback.

  • Japanese bridging study confirmed efficacy across all patient types, supporting conditional approval in Japan.

  • RAMP 205 in pancreatic cancer showed an 83% response rate with full-dose chemo, with expanded cohort data due mid-year.

  • G12D inhibitor (VS-7375) demonstrated 58% response in pancreatic and 69% in lung cancer, with U.S. trials showing improved tolerability.

Strategic outlook and future plans

  • Awaiting potential NCCN guideline inclusion, which could further boost growth.

  • RAMP 301 could expand the addressable U.S. market to 6,000–10,000 patients if wild type is included.

  • U.S. phase I study of VS-7375 is progressing, with single-agent and combination arms in multiple cancers.

  • Plans to pursue both single-agent and combination strategies in front-line lung and pancreatic cancers.

  • Company-sponsored events will provide key data updates on pipeline progress throughout the year.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Verastem earnings date

Logotype for Verastem Inc
Q4 202517 Mar, 2026
Verastem
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Verastem earnings date

Logotype for Verastem Inc
Q4 202517 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Verastem Inc is a development-stage biopharmaceutical company primarily focused on the development and commercialization of new medicines aimed at improving the lives of patients diagnosed with cancer. The company is engaged in advancing a pipeline of novel small-molecule drugs that target critical signaling pathways involved in cancer cell survival and tumor growth. These pathways include RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition, which are central to the company's research and development efforts. The company is headquartered in Needham, Massachusetts, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage